Psoriasis and Kidney Disease: What the Research Shows
Psoriasis and kidney disease affect organs that seem to have nothing in common, yet a growing body of population research shows that people with moderate to severe psoriasis carry a measurably higher risk of chronic kidney disease (CKD) than people without it – and a few of the systemic drugs used for severe psoriasis are cleared through the kidneys and need renal monitoring while you are on them. This matters most if you have long-standing plaque psoriasis and are on, or considering, an oral systemic drug such as cyclosporine or methotrexate, or if psoriatic arthritis has you reaching for anti-inflammatory painkillers regularly. This guide looks at what the large cohort studies actually found, why the two conditions cluster together, which psoriasis treatments carry real renal considerations, how screening and costs work in India, and how an integrative Ayurvedic approach adapts when kidney function is reduced.
What Is Chronic Kidney Disease, and Why Does It Matter for Psoriasis?
Chronic kidney disease is a gradual, often silent loss of kidney filtering capacity, staged from 1 (near-normal function) to 5 (kidney failure requiring dialysis or transplant) based on estimated glomerular filtration rate (eGFR) and the amount of protein leaking into urine. Diabetes and high blood pressure are the two leading causes worldwide, and both of these conditions are already known to occur more often in people with psoriasis than in the general population. Early CKD rarely causes symptoms, which is exactly why it matters here: a person with psoriasis who feels otherwise fine can still have reduced kidney function, and that reduced function changes how safely certain psoriasis drugs can be used. A dermatologist cares about this because psoriasis is a systemic inflammatory disease intertwined with metabolic syndrome, obesity, and cardiovascular risk – the same territory that drives most chronic kidney disease – so the two conditions are rarely unrelated bystanders.
How Strong Is the Evidence Linking Psoriasis and Kidney Disease?
A Large UK Population-Based Cohort Study
The most widely cited evidence comes from a population-based cohort study using the UK’s General Practice Research Database, published in the BMJ. Researchers followed 143,883 patients with psoriasis (136,529 classified as mild, 7,354 as severe based on treatment patterns) against 689,702 matched people without psoriasis. After adjusting for other risk factors, the hazard ratio for developing moderate to advanced CKD (stages 3 to 5) was 1.05 overall, 0.99 in mild psoriasis (not statistically significant), and 1.93 in severe psoriasis – close to double the risk. A companion nested cross-sectional analysis of 8,731 psoriasis patients matched to 87,310 controls found a clear dose-response pattern by the amount of body surface area (BSA) affected: an adjusted odds ratio of 0.89 for mild disease (2% BSA or less), rising to 1.36 for moderate disease (3 to 10% BSA) and 1.58 for severe disease (more than 10% BSA). Disease duration showed a similar gradient, from 0.90 in people with psoriasis under two years to 1.24 in those with psoriasis for ten years or more.
A Meta-Analysis Confirms the Pattern
A systematic review and meta-analysis pooling data from multiple studies and well over 700,000 patients found a pooled hazard ratio of roughly 1.65 for chronic kidney disease and 1.37 for end-stage renal disease (ESRD) in people with psoriasis compared with the general population, with the risk climbing further as psoriasis severity increased. Reassuringly, a related narrative review covering biologic drug classes concluded that modern biologics, as a group, do not appear to worsen renal function in most treated patients, a point covered in more detail below.
Shared Biology: Why Would Skin Inflammation Affect the Kidneys?
Psoriasis is not confined to the skin. The same TNF-alpha, IL-17, and IL-23 driven inflammation that produces plaques also circulates systemically, contributing to endothelial dysfunction, insulin resistance, and vascular damage – the same chain of events increasingly linked to cardiovascular risk in psoriasis. Chronic low-grade inflammation of this kind is a recognised contributor to kidney damage over time, independent of any single risk factor. On top of this direct pathway, psoriasis clusters with obesity, hypertension, and type 2 diabetes, which are themselves the leading causes of CKD globally, so some of the association reflects shared risk factors rather than psoriasis acting alone. A third contributor is treatment-related: people with psoriatic arthritis often rely on NSAIDs for joint pain, and regular, long-term NSAID use is an independent, well-documented cause of kidney injury, adding a layer of risk that has nothing to do with psoriasis biology itself but everything to do with how it is often managed.
Could Psoriasis Treatments Themselves Affect Your Kidneys?
Several drugs used for moderate to severe psoriasis interact directly with kidney function, which is why renal blood tests are a routine part of systemic psoriasis care.
- Cyclosporine is the systemic psoriasis drug with the clearest, best-documented nephrotoxic potential. It narrows blood vessels within the kidney and can cause structural damage with prolonged or high cumulative use, which is why treatment courses are typically time-limited and why blood pressure and serum creatinine are checked regularly throughout treatment, as covered in our guide to cyclosporine for psoriasis.
- Methotrexate is cleared largely by the kidneys, so reduced kidney function slows its elimination and raises the risk of serious toxicity, including bone marrow suppression and mucositis. Doctors typically avoid methotrexate altogether once kidney function falls below a certain threshold, and reduce the dose or monitor more closely at milder levels of impairment; combining it with regular NSAID use raises this risk further. More detail is available in our article on the side effects of methotrexate.
- Acitretin, an oral retinoid, is not considered significantly nephrotoxic, though routine blood monitoring is still standard practice, as described in our acitretin guide.
- Biologics (TNF, IL-17, and IL-23 inhibitors) have a reassuring renal safety profile so far. A retrospective study of 601 patients with severe psoriasis treated continuously for at least two years found no significant change in eGFR or CKD stage regardless of biologic class, with only 2.2% progressing to CKD; patients on IL-17 inhibitors specifically maintained a stable CKD stage throughout. A separate analysis of over 6,000 adults found biologics and methotrexate carried comparable renal safety overall. Case reports of patients with pre-existing kidney disease, including some on dialysis, who were treated with IL-17 inhibitors for severe psoriasis describe skin clearance without renal deterioration, and occasionally modest improvement. Patient factors such as diabetes, older age, pre-existing kidney impairment, and high cholesterol appear to drive renal outcomes more than the specific biologic chosen. More on how biologics compare is in our biologics for psoriasis overview.
Treatment Considerations When Both Conditions Are Present
- Baseline and periodic renal testing – standard practice before starting cyclosporine or methotrexate, and repeated at intervals your dermatologist sets based on your results and risk factors.
- Rethinking routine NSAID use – if psoriatic arthritis pain means frequent NSAIDs, it is worth discussing alternatives with your doctor if kidney function is already reduced or trending downward.
- Controlling blood pressure and blood sugar – doubly important here, since both conditions sit at the intersection of psoriasis and CKD risk.
- Biologics as a reasonable alternative – when renal impairment limits the use of cyclosporine or methotrexate, biologics are often a sensible systemic option, under specialist guidance and with ongoing monitoring.
- Coordinated care – when CKD is confirmed alongside moderate to severe psoriasis, your dermatologist and nephrologist ideally communicate before any new systemic drug is started or changed.
Screening and Cost in India
Basic kidney screening is simple and inexpensive: a serum creatinine test (used to calculate eGFR) typically costs around ₹200 to ₹400 at diagnostic labs in Bangalore and other Indian cities, and a urine albumin-to-creatinine ratio (ACR) test, which can detect kidney damage before eGFR falls, adds roughly ₹300 to ₹600 more. If results suggest CKD, further workup such as an ultrasound of the kidneys and urinary tract (KUB) and an electrolyte panel usually adds a few thousand rupees. For patients who do progress to advanced CKD or end-stage renal disease, the Ayushman Bharat PM-JAY scheme covers hemodialysis and peritoneal dialysis, along with related procedures like AV fistula creation, cashlessly at empanelled hospitals, up to a family cap of ₹5 lakh per year; the government’s Pradhan Mantri National Dialysis Programme separately runs free or subsidised dialysis centres aimed at patients who cannot otherwise afford regular treatment. These schemes cover the kidney care itself, not routine psoriasis treatment, so the two costs are tracked separately.
How This Fits an Integrative, Ayurvedic Approach
In our clinical assessment, psoriasis correlates most closely with Kushta, reflecting a Vata-Kapha-Pitta imbalance addressed through the longer-term protocols described in our Ayurvedic psoriasis treatment in Bangalore guide. Reduced kidney function changes how that plan is built: several classical formulations and Panchakarma procedures, including dehydrating purgation protocols such as Virechana, need to be modified, used cautiously, or avoided altogether when renal clearance is compromised, and certain herbal ingredients require careful sourcing and dosing review in this setting. This is precisely why a confirmed CKD diagnosis, or even a borderline creatinine result, should always be disclosed to your treating Ayurvedic physician before starting or continuing any internal medicine or Panchakarma protocol. None of this replaces your nephrologist: when CKD is confirmed, renal management continues on its own track, with Ayurvedic care adapted around it rather than in place of it.
When to See a Doctor
If you have moderate to severe psoriasis and notice persistent swelling around the ankles or eyes, unusual fatigue, foamy urine, changes in how often you urinate, or difficult-to-control blood pressure, it is worth asking your doctor for a kidney function check, especially if you are on, or have previously taken, cyclosporine or methotrexate. Equally, if you already have CKD and are being considered for a systemic psoriasis drug, make sure your dermatologist has your latest renal results before treatment starts. You can also book a consultation for a personalized assessment that looks at your psoriasis treatment alongside your overall metabolic and kidney health.
Frequently Asked Questions
1. Does psoriasis directly cause kidney disease?
Not in a simple, direct sense. Large cohort studies show a clear statistical association, especially with severe psoriasis, most likely explained by shared systemic inflammation, overlapping risk factors like obesity, diabetes and hypertension, and the renal effects of some psoriasis drugs, rather than psoriasis causing kidney failure on its own.
2. How much does severe psoriasis raise the risk of chronic kidney disease?
A UK population-based cohort study of over 830,000 people found an adjusted hazard ratio of 1.93 for moderate to advanced CKD in patients with severe psoriasis, compared with no significant increase in mild psoriasis. A separate meta-analysis of over 700,000 patients found a pooled hazard ratio of about 1.65 for CKD, rising with disease severity.
3. Which psoriasis drugs are hardest on the kidneys?
Cyclosporine has the clearest, best-documented nephrotoxic potential and requires regular blood pressure and creatinine monitoring. Methotrexate is cleared by the kidneys, so reduced kidney function raises toxicity risk and often requires dose reduction or avoidance. Acitretin is not considered significantly nephrotoxic but still needs routine monitoring.
4. Are biologics safe to use if I already have reduced kidney function?
Evidence so far is reassuring: studies tracking patients on biologics for two years or more found little to no change in kidney function regardless of drug class, and some patients with pre-existing kidney disease showed stable or improved renal markers alongside skin clearance. Patient-level factors like diabetes and baseline kidney impairment matter more than the specific biologic chosen, and this should always be discussed with your treating doctor.
5. Does Ayushman Bharat cover dialysis if I develop kidney disease alongside psoriasis?
Yes. Ayushman Bharat PM-JAY covers hemodialysis and peritoneal dialysis, along with related procedures, cashlessly at empanelled hospitals, up to a family cap of five lakh rupees per year. The separate Pradhan Mantri National Dialysis Programme also runs free or subsidised dialysis services in many districts. Routine psoriasis treatment is tracked and covered separately from kidney care.
6. How often should kidney function be tested during systemic psoriasis treatment?
This depends on the specific drug and your individual risk factors, so it is set by your treating dermatologist rather than a fixed universal schedule. In general, testing is more frequent in the first few months of cyclosporine or methotrexate treatment and continues at regular intervals for as long as you remain on either drug.
Sources and References
- Wan, M.T. et al., “Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study,” BMJ, 2013.
- “Association of psoriasis with chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis,” PMC / National Library of Medicine, 2023.
- Methotrexate Summary of Product Characteristics, electronic Medicines Compendium (medicines.org.uk), renal impairment dosing and monitoring sections.
- Narrative review on biologic therapy and renal outcomes in psoriasis, Frontiers in Immunology, as summarised by the American Journal of Managed Care.
- Ministry of Health and Family Welfare, Government of India – Pradhan Mantri National Dialysis Programme and Ayushman Bharat PM-JAY dialysis coverage information.
- DermNet NZ and American Academy of Dermatology – psoriasis comorbidities and systemic therapy monitoring resources.
This article is intended for general educational purposes and does not replace personalized medical advice. Anyone with psoriasis who is concerned about kidney health, or who is starting a new systemic treatment, should consult a qualified doctor for proper testing and guidance.
